Tissue Repair
BPC-157 + KPV
Gut healing blend; gut-repair stack
Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend
This BPC-157 + KPV entry draws on 3 cited sources published 2008 to 2021. The evidence available is graded Anecdotal + Animal Studies on this site's scale. Dosing is reported as described in the literature rather than as guidance. Sources checked .
At a glance
- Class
- Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend
- Drug class
- Tissue Repair
- Structure
- Co-formulated vial: BPC-157 (15-aa GEPPPGKPADDAGLV) + KPV (tripeptide Lys-Pro-Val, the C-terminal alpha-MSH fragment)
- Route
- SC / Oral
- Half-life
- BPC-157 less than 30 min (IV and IM, animal data); KPV ~minutes (rapid clearance)
- Evidence tier
- Anecdotal + Animal Studies
- Availability
- Compounding Restricted
Mechanism of action
BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it.
Reported areas of research
Gut mucosal repair; inflammatory bowel symptom support; intestinal-barrier restoration; combined healing + anti-inflammatory action commonly stacked for leaky-gut/IBD anecdotal protocols
Items above describe areas studied in published peptide literature, not approved indications. Most peptides catalogued here are not FDA-approved for human use.
Dosage protocols reported in literature
250-500 mcg BPC-157 + 500-1000 mcg KPV SC daily near area of concern, or oral compounded form 1-2x daily. Cycle 4-6 weeks on / 2-4 weeks off
Reported research dosing only. This is not a clinical recommendation. Consult a qualified clinician before any human use.
Known concerns and limitations
Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication
Compared with
BPC-157 + KPV has published head-to-head comparisons with 7 compounds that share its pharmacological class: mechanism, half-life, reported research dosing, evidence tier and regulatory status side by side.
Frequently asked questions
What dosing is reported for BPC-157 + KPV in research literature?
Published peptide research reports the following dosing approach for BPC-157 + KPV: 250-500 mcg BPC-157 + 500-1000 mcg KPV SC daily near area of concern, or oral compounded form 1-2x daily. Cycle 4-6 weeks on / 2-4 weeks off. This is a research reference, not a clinical recommendation.
How is BPC-157 + KPV administered in research?
BPC-157 + KPV is administered via the following routes in published studies: SC / Oral.
What is the reported half-life of BPC-157 + KPV?
The reported half-life of BPC-157 + KPV is BPC-157 less than 30 min (IV and IM, animal data); KPV ~minutes (rapid clearance).
Is BPC-157 + KPV FDA-approved?
No. BPC-157 + KPV is not an FDA-approved drug. PeptideHelper.org catalog status: Compounding Restricted.
What level of evidence supports BPC-157 + KPV?
The current evidence base for BPC-157 + KPV is best characterised as: Anecdotal + Animal Studies. See the methodology page for the full evidence-tier rubric.
What side effects are reported for BPC-157 + KPV?
Known concerns reported in the literature for BPC-157 + KPV include: Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication. Always consult a qualified clinician before any human use.
Is there anyone who should not use BPC-157 + KPV?
No formal contraindications are established for BPC-157 + KPV, because it is not an FDA-approved medicine and no approved label exists to define them. That is an absence of regulatory review rather than evidence of safety. Reported concerns from the literature are: Both components are research compounds with limited human safety data; injection-site reactions; theoretical immune modulation; not FDA-approved for any indication. Always consult a qualified clinician before any human use.
How does BPC-157 + KPV work?
The mechanism of action reported for BPC-157 + KPV in the literature: BPC-157 promotes angiogenesis (VEGFR2), stabilises gut barrier function, and accelerates epithelial repair; KPV exerts NF-kB-suppressing anti-inflammatory activity at the colonic mucosa via melanocortin pathway intermediates. Layered: BPC-157 drives repair while KPV damps the inflammatory signal that delays it..
What is BPC-157 + KPV studied for?
BPC-157 + KPV has been studied in the published literature for: Gut mucosal repair; inflammatory bowel symptom support; intestinal-barrier restoration; combined healing + anti-inflammatory action commonly stacked for leaky-gut/IBD anecdotal protocols. These are areas of research, not established clinical uses unless the compound is FDA-approved for them.
What is BPC-157 + KPV?
BPC-157 + KPV is classified as: Cytoprotective pentadecapeptide (BPC-157) + alpha-MSH-derived tripeptide (KPV) blend. Also known as: Gut healing blend; gut-repair stack.
Drug class
- Tissue-repair peptides, see all peptides tagged Tissue-repair.
- Anti-inflammatory peptides, see all peptides tagged Anti-inflammatory.
Research focus area
All peptides studied for Tissue Repair, ranked by evidence tier and regulatory status.
Primary sources
- Sikiric P et al. Stable gastric pentadecapeptide BPC 157 — review of pharmacology. Curr Pharm Des 2018. PMID 29804522
- Dalmasso G et al. KPV: a novel anti-inflammatory peptide derived from alpha-MSH inhibits epithelial pro-inflammatory pathways. Gastroenterology 2008. PMID 18054553
- Seiwerth S et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Front Pharmacol 2021. PMID 34267654
Open the full interactive PeptideHelper.org reference to compare peptides side-by-side, evaluate stacks, and explore the catalog.
Spot an error or a missing source on this page? Suggest a correction. Corrections are logged and surfaced in the next review.
Loading interactive view…